2cureX AB (publ) (STO:2CUREX)
Sweden · Delayed Price · Currency is SEK 1.280
-0.100 (-7.25%)
Jan 21, 2026, 5:23 PM CET
2cureX AB Company Description
2cureX AB (publ) operates as a medtech company in Europe.
The company’s principal product is IndiTreat, an IVD test, which helps to predict cancer patient’s response and resistance to different drugs and select the appropriate treatment.
It is also conducting various clinical programs for IndiTreat for colorectal, ovarian, and pancreatic cancers.
In addition, the company offers research and consulting services. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.
2cureX AB (publ)
| Country | Sweden |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Nathaniel Hutley |
Contact Details
Address: Fruebjergvej 3 Copenhagen, 2100 Denmark | |
| Phone | 45 22 11 53 99 |
| Website | 2curex.com |
Stock Details
| Ticker Symbol | 2CUREX |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0010468124 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Nathaniel Hutley | Interim Chief Executive Officer and Director |
| Ole Thastrup VD | Co-Founder and Chairman |
| Grith Hagel | Co-Founder, Vice President of Innovation and Director |
| Kenneth Graabek Johansen | Chief Financial Officer |
| Jacob Thastrup | Chief Technology Officer |
| Manuel Fernandez | Director Quality and Regulatory Affairs |